Clinical analysis of lasting remission of high-risk acute lymphoblastic leukemia in children after severe infection

VernacularTitle:儿童高危急性淋巴细胞白血病重症感染后持久缓解临床分析
Author: Yujie GUAN ; Yanna MAO ; Yingying ZHU ; Jianwen ZHOU ; Chaorong WANG ; Wei LIU
From: Journal of Leukemia & Lymphoma 2021;30(3):171-174
CountryChina
Language:Chinese
Abstract: Objective:To investigate the clinical characteristics of children with high-risk acute lymphoblastic leukemia (ALL) receiving lasting remission after severe infection.Methods:The data of 3 children with high-risk ALL who were treated in Children's Hospital Affiliated of Zhengzhou University in 2014, 2015 and 2017 were analyzed retrospectively. The clinical and laboratory characteristics of all patients were also analyzed, and the relevant literatures were reviewed.Results:All 3 children were clinically classified as high-risk ALL with severe infection. A variety of anti-infective drugs and blood products were used in the treatment, and all achieved lasting remission.Conclusions:Children with high-risk ALL after severe infection can acquire lasting remission, which may be related with the production of infection stimulating inflammatory factors and cytokines to activate certain immune pathways, or various kinds of antibiotics, blood products participating in the immune regulation to make the body regain the immune surveillance function of the tumor cells.